Compare IIIV & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IIIV | REPL |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 434.2M | 407.1M |
| IPO Year | 2018 | 2018 |
| Metric | IIIV | REPL |
|---|---|---|
| Price | $20.04 | $10.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 9 |
| Target Price | ★ $33.20 | $5.67 |
| AVG Volume (30 Days) | 409.0K | ★ 5.4M |
| Earning Date | 05-07-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.25 |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.05 | N/A |
| Revenue Next Year | $8.07 | N/A |
| P/E Ratio | $247.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.47 | $1.50 |
| 52 Week High | $33.97 | $13.24 |
| Indicator | IIIV | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 46.45 | 70.76 |
| Support Level | $18.82 | $8.25 |
| Resistance Level | $23.62 | $10.71 |
| Average True Range (ATR) | 0.93 | 0.88 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 30.73 | 74.33 |
i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.